All Stories

  1. First steps in the treatment of advanced Parkinson’s disease with foslevodopa/foscarbidopa continuous subcutaneous infusion
  2. Prevalence and Associations of Poor Sleep in Patients with Relapsing-Remitting Multiple Sclerosis on Disease-Modifying Therapy
  3. Differences in acute ischemic stroke treatment: A cross-sectional study from international Registry of Stroke Care Quality (RES-Q)
  4. Thermodynamic Signatures of Blood Plasma Proteome in Neurodegenerative Pathologies
  5. Eficacia en la vida real del fingolimod en pacientes con esclerosis múltiple en Bulgaria
  6. Platelets’ Nanomechanics and Morphology in Neurodegenerative Pathologies
  7. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial
  8. Efficacy and safety of adjunctive cenobamate: Post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications
  9. Morphometry and Stiffness of Red Blood Cells—Signatures of Neurodegenerative Diseases and Aging
  10. Red Blood Cells’ Thermodynamic Behavior in Neurodegenerative Pathologies and Aging
  11. The development and use of the European academy of neurology guideline on palliative care in advanced progressive multiple sclerosis
  12. Translation, adaptation and validation of the Bulgarian version of the King’s Parkinson’s Disease Pain Scale
  13. Clinical Correlation between Hormonal Status and Autonomic Nervous System Function in Patients with Fibromyalgia
  14. Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description
  15. Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity
  16. EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis
  17. Neurophysiological Findings in Chronic Pain Syndromes
  18. Repetitive Transcranial Magnetic Stimulation over Two Target Areas, Sham Stimulation and Topiramate in the Treatment of Chronic Migraine
  19. Pitfals in recognition and management of trigeminal neuralgia
  20. Palliative care in multiple sclerosis: European guideline
  21. EAN guideline on palliative care of people with severe, progressive multiple sclerosis
  22. Safety of adjunctive treatment with cenobamate in patients with uncontrolled focal seizures – Authors' reply
  23. Update on the Management of Parkinson’s Disease for General Neurologists
  24. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial
  25. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
  26. Novel Approach for Objective Quantification of Locomotor Disturbaces in Low Back Pain
  27. Neutralizing Antibodies against Interferon‑beta in Bulgarian Adolescent Multiple Sclerosis Patients
  28. Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis
  29. Do Binding Antibodies Predict Neutralizing Antibody Development in Multiple Sclerosis Patients?
  30. Starvation, Strachan's syndrome, and postgastroplasty syndrome
  31. Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes
  32. F-Wave in the Upper Extremities of Patients with Primary Torsion Dystonia
  33. Serum levels of EBVNA-IgG and EBVCA-IgG in patients with multiple sclerosis
  34. Trigeminal Nerve Reflexes in Chronic Pain Syndromes
  35. Back pain
  36. Back pain
  37. Trigeminal Neuralgia
  38. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
  39. ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study
  40. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
  41. Diagnostic value of combinations of symptoms of migraine and tension-type headache included in the diagnostic criteria for children and adolescents in the international classification of headache disorders 2nd edition
  42. Chromosomal radiosensitivity in patients with multiple sclerosis
  43. How Does Fingolimod (Gilenya®) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis?
  44. Evaluation of diagnostic and prognostic value of clinical characteristics of Migraine and Tension type headache included in the diagnostic criteria for children and adolescents in International Classification of Headache Disorders - second edition
  45. Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group
  46. Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
  47. Prevalence of Dementia and Mild Cognitive Impairment in a Bulgarian Urban Population
  48. A basic diagnostic headache diary (BDHD) is well accepted and useful in the diagnosis of headache. A multicentre European and Latin American study
  49. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial
  50. Implementation and impact of headache guidelines
  51. Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease
  52. Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing—remitting multiple sclerosis
  53. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
  54. Transient Mutism and Pathologic Laughter in the Course of Cerebellitis
  55. Mechanisms of tizanidine action on spasticity
  56. Mechanisms of baclofen action on spasticity
  57. Rationale and Design of a Randomized, Double-Blind, Parallel-Group Study of Terutroban 30 mg/day versus Aspirin 100 mg/day in Stroke Patients: The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients wi...
  58. Determination of plasma aminothiols by high performance liquid chromatography after precolumn derivatization with N-(2-acridonyl)maleimide
  59. P013 Neurophysiological study on facial F-waves in patients with primary headache and with Parkinson's disease
  60. P234 Monitoring of drug efficacy on different types of tremor in Parkinson's disease
  61. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis
  62. Therapeutic Use of Nicergoline
  63. S.01.02 Tension-type headache
  64. 1.184 Cognitive impairments in patients with early Parkinson's disease
  65. Abnormal Modulatory Influence of Diffuse Noxious Inhibitory Controls in Migraine and Chronic Tension-Type Headache Patients
  66. The epidemiology of multiple sclerosis in Europe
  67. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis
  68. Acute reversible parkinsonism in Epstein–Bbarr virus–related encephalitis lethargica‐like illness
  69. Pain and tension-type headache: a review of the possible pathophysiological mechanisms
  70. Lower limb SSEP changes in stroke—predictive values regarding functional recovery
  71. Electrophysiological evidence for trigeminal neuron sensitization in patients with migraine.
  72. Trigemino-Cervical Reflex in Patients with Headache
  73. Clinical and electromyographic assessment of essential tremor treatment
  74. Antiphospholipid syndrome and dystonia-parkinsonism
  75. Electrophysiological evidence for trigeminal neuron sensitization in patients with migraine
  76. Antiphospholipid syndrome and dystonia-parkinsonism
  77. Electromyographic differentiation of tremors
  78. A cross-over clinical and electromyographic assessment of treatment for parkinsonian tremor
  79. Clinical and electromyographic examinations of patients with tremor after chronic occupational lead exposure
  80. Antiphospholipid syndrome and dystonia–parkinsonism. A case report
  81. Prevalence of Parkinson’s Disease in Bulgaria
  82. Effects of Sleep on Spinal Nociceptive Reflexes in Humans
  83. Clinical and electromyographic examinations of Parkinsonian tremor
  84. Asymmetrical reduction of the nociceptive flexion reflex threshold in cluster headache
  85. Asymmetrical Reduction of the Nociceptive Flexion Reflex Threshold in Cluster Headache
  86. Acupuncture for episodic tension-type headache: a multicentre randomized controlled trial
  87. Effects of hypnosis on diffuse noxious inhibitory controls
  88. Clinical and electromyographic characteristics of tremor in patients with depression
  89. Clinical and Electromyographic Examinations of Patients with Essential Tremor
  90. Prevalence of Parkinson’s Disease in Bulgarian Gypsies
  91. Neurophysiological approach to the study of cluster headache
  92. Different effect of high doses of naloxone on spinal reflexes in normal subjects and chronic paraplegic patients
  93. Prevalence of Multiple Sclerosis in Gypsies and Bulgarians
  94. Contralateral hemi-parkinsonism and atypical tremor after stroke (a case report)
  95. Parkinsonian Syndrome as a Neurological Manifestation of Behcet's Disease
  96. 1-02-06 Differential diagnosis of amyotrophic lateral sclerosis and similar syndromes
  97. Prevalence of Multiple Sclerosis in Bulgaria
  98. P169 Differential diagnosis of limb girdle syndromes
  99. Writer’s Cramp and Tremor Due to Brain Tumor
  100. Vestibular and auditory influences on segmental motoneuron excitability — a comparative study
  101. Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy and Skin Changes (Poems) Syndrome
  102. A comparative study of methods for estimation of presynaptic inhibition
  103. A Comparison of Methods to Assess the Excitability of Lower Motoneurones